# Adarza BioSystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adarza-biosystems

- Industry: Biotechnology
- Headquarters: St. Louis, US
- Website: www.adarzabio.com
- Total disclosed funding: $29M
- Latest round: Series C (Jan 19, 2017)
- Investors on record: 4

## About

Adarza BioSystems, Inc. specializes in advanced biosensing technology, delivering innovative solutions for immune response analysis and diagnostics in the healthcare sector.Founded in 2008 and headquartered in St. Louis, US, Adarza BioSystems, Inc. focuses on biosensing technology. The company has raised a total of USD 12.78 mn, with its most recent funding round being a Series D in November 2019, involving investors such as 3x5 Partners and Lightchain Capital. Bryan Witherbee is the CEO of the company.Adarza BioSystems specializes in advanced biosensing technology, with its core product offering centered around the ZIVA™ platform. This innovative technology utilizes laser-based methodologies to provide high-definition insights into the immune response, particularly in relation to SARS-CoV-2 and other health conditions. The platform is designed to address critical end-use cases in the field of immunology and infectious disease diagnostics by enabling researchers and healthcare professionals to obtain precise quantifications of immune markers. Adarza’s customer base primarily includes research laboratories, diagnostic companies, and healthcare institutions that require sophisticated tools for conducting detailed immune response analyses. Their products are marketed in various geographical locations, including North America, Europe, and select markets in Asia, reflecting a commitment to global health advancements.Adarza BioSystems generates revenue through a structured business model that includes partnerships and direct sales of its proprietary technologies. The company engages with clients primarily through B2B transactions, offering their flagship ZIVA™ platform and associated custom assays for a range of applications. These engagements often involve strategic collaborations with healthcare providers and research organizations that seek to enhance their diagnostic capabilities. Clients typically acquire products through direct purchases, with options for subscription-based services that provide ongoing access to new assays and updates to the platform. Specific pricing structures for these offerings are designed to accommodate varying client needs, ensuring that healthcare institutions and researchers can efficiently integrate Adarza’s technology into their workflows.In November 2019, Adarza BioSystems, Inc. raised USD 12.78 mn in Series D funding to support its growth initiatives. The company plans to leverage this funding for developing new products and expanding its market presence. Specific efforts include the introduction of new assays related to immunology and infectious diseases, with targeted launches expected in the coming years. Additionally, Adarza aims to expand its operations into new geographic regions, focusing on markets in Asia and Europe to enhance its global footprint.

## Funding rounds

- Series C, Jan 19, 2017, $17M — RiverVest Ventures Partners
- Series B, Mar 22, 2016, $5M — N47, Cultivation Capital, Lewis & Clark Ventures
- Series A, Oct 6, 2014, $6.8M — N47, Cultivation Capital

## Investors

- N47 (https://capitalatlas.ai/funds/n47) — Series A, Series B
- Cultivation Capital (https://capitalatlas.ai/funds/cultivation-capital) — Series A, Series B
- Lewis & Clark Ventures (https://capitalatlas.ai/funds/lewis-clark-ventures) — Series B
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series C